AML provides an excellent disease model to further investigate the relationship between PRL2 and PTEN in tumorigenesis, since PTEN is frequently observed to be downregulated in the disease, while overexpression of PRL2 is a prognostic marker of adverse clinical outcomes in patients with AML. This evidence concerns the gene PTP4A2 and acute myeloid leukemia.